Glucose and glycogen are initial materials involved in the glycometabolism. A chronically irregular diet could result in the disorders of glycometabolism, which was manifested by the gradual deterioration of glucose tolerance over time, leading to the increased fasting blood glucose or impaired glucose tolerance. The clinical manifestations of glycometabolism-related disorder are hyperglycemia or hypoglycemia, which might eventually contribute to some serious diseases, such as diabetes, G6PD deficiency, obesity and malnutrition.
In addition, favored glycolysis under aerobic conditions (aerobic glycolysis), or the Warburg effect, the transition from oxidative phosphorylation to glycolysis, accompanied by the accumulation of lactate by-products in the surrounding microenvironment and 20-30 times faster rate of glucose metabolism than the complete oxidation of glucose in the mitochondria, represents the most typical change observed in the metabolism of cancer cells. Therefore, a key to selective killing of cancer cells lies in their dependence on glycolysis. Targeting tumor cell metabolism has become a successful approach to the prevention or treatment of cancer. Most efforts have focused on the use of small molecules to inhibit the function of metabolic enzymes, which has been comprehensively reviewed elsewhere. Increasing evidence supports many glycolytic enzymes and transporters as candidates for cancer treatment.
TargetMol’s Glycometabolism Compound Library collects 638 glycometabolism-related compounds, targeting GLUTs, Hexokinase（HK）, Pyruvate Kinase（PK ）, phosphofructokinase（PFK）, IDH1/2, LDH, AMPK, etc. It is a powerful tool for research in glycometabolism-related disorders and cancer.
|100 μL * 10 mM (in DMSO)||10374.00|
|250 μL * 10 mM (in DMSO)||17370.00|